Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0208

Scientific exchange · Dr. Noor Sato

01 Feb 2026 · In person · Dr. Noor Sato, Royal Melbourne Hospital · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0208—

Capture insight from this engagement

Location: Royal Melbourne Hospital
Therapeutic area: Neurology
Country: Australia
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Drug interactions
Dosing in hepatic impairment

Scientific content used

LMV persistence data summary
Chronic migraine scientific platform

Questions raised

Is there guidance on switching from a monoclonal antibody?
What is the persistence rate at 18 months in real-world cohorts?

Notes

Scientific exchange with primary care physician at Royal Melbourne Hospital. Discussed drug interactions, dosing in hepatic impairment.

Insights captured (1)

Capture insight

INS-0002High
Drug interactions
Drug interactions: recurring question reported by primary care physician (AU).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 4
Depth of exchange: 3
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0208

Audit history (0)

All create, update and approval events for this record

No audit events in sample data